title: Hyperthermic intraperitoneal chemotherapy with paclitaxel or cisplatin in patients with stage III-C/IV ovarian cancer. Is there any difference?
abstract: OBJECTIVE
  To compare the results of the administration of HIPEC with Paclitaxel or Cisplatin after cytoreduction in patients with stage IIIC-IV ovarian cancer, especially focused on disease-free survival.
  
  
  METHODS
  We retrospectively analyzed a consecutive series of patients operated after being diagnosed with stage III-C/IV serous epithelial ovarian carcinoma. Patients included in the study were treated between January 2008 and March 2015. After cytoreduction, Paclitaxel (doses of 60 mg/m(2)O or Cisplatin (doses of 75 mg/m(2)) were used.
  
  
  RESULTS
  A total of 111 patients were included. Median age was 61 years. In 60 of them (54%) Paclitaxel was used during HIPEC treatment and 51 patients (46%) were treated with Cisplatin. PCI was similar between groups (PCI = 11 in both cases). Median follow up was 34 months (12-96 months). The median disease free survival in Paclitaxel Group was 27 months and 33 months in Cisplatin Group (p = 0.551). In patients treated with Paclitaxel disease free survival rates at 1, 2, and 3 years were 79%, 60% and 46%. In patients treated with Cisplatin disease free survival at 1, 2, and 3 years were 64%, 50% and 40% respectively. After a multivariate analysis, incomplete cytoreduction (HR: 6.54, 95% CI 2.98-10.17, p < 0.01) and PCI >11 (HR: 2.15, 95% CI 1.42-6.68, p < 0.05) were identified as independent factors associated with a reduced disease-free survival. Cystotatic used was not relevant regarding disease free survival analysis.
  
  
  CONCLUSIONS
  HIPEC with paclitaxel or cisplatin after cytoreduction in patients with ovarian cancer IIIC-IV has not shown different results in disease-free survival outcomes.
authors: Unidad De Cirugía De La Carcinomatosis Peritoneal, Departamento De Cirugía General, Spain; Peritoneal Carcinomatosis Unit, Department of Surgery, Virgen de la Arrixaca University Hospital, Murcia, Spain. Electronic address: cascalescirugia@gmail.com.
authors: P
authors: P
authors: Cascales-Campos
authors: Unidad De Cirugía De La Carcinomatosis Peritoneal, Departamento De Cirugía General, Spain; Peritoneal Carcinomatosis Unit, Department of Surgery, Virgen de la Arrixaca University Hospital, Murcia, Spain.
authors: V
authors: V
authors: López-López
authors: Unidad De Cirugía De La Carcinomatosis Peritoneal, Departamento De Cirugía General, Spain; Peritoneal Carcinomatosis Unit, Department of Surgery, Virgen de la Arrixaca University Hospital, Murcia, Spain.
authors: J
authors: J
authors: Gil
authors: Radiology Department, Memorial Sloan-Kettering Cancer Center, USA; Peritoneal Carcinomatosis Unit, Department of Surgery, Virgen de la Arrixaca University Hospital, Murcia, Spain.
authors: J
authors: J
authors: Arévalo-Pérez
authors: Unidad De Ginecología Oncológica, Servicio De Ginecología y Obstetricia, Spain; Peritoneal Carcinomatosis Unit, Department of Surgery, Virgen de la Arrixaca University Hospital, Murcia, Spain.
authors: A
authors: A
authors: Nieto
authors: Unidad De Ginecología Oncológica, Servicio De Ginecología y Obstetricia, Spain; Peritoneal Carcinomatosis Unit, Department of Surgery, Virgen de la Arrixaca University Hospital, Murcia, Spain.
authors: F
authors: F
authors: Barceló
authors: Unidad De Cirugía De La Carcinomatosis Peritoneal, Departamento De Cirugía General, Spain; Peritoneal Carcinomatosis Unit, Department of Surgery, Virgen de la Arrixaca University Hospital, Murcia, Spain.
authors: E
authors: E
authors: Gil
authors: Unidad De Cirugía De La Carcinomatosis Peritoneal, Departamento De Cirugía General, Spain; Peritoneal Carcinomatosis Unit, Department of Surgery, Virgen de la Arrixaca University Hospital, Murcia, Spain.
authors: P
authors: P
authors: Parrilla
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000077216:Carcinoma, Ovarian Epithelial; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D065426:Cytoreduction Surgical Procedures; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006979:Hyperthermia, Induced; D007274:Injections, Intraperitoneal; D008875:Middle Aged; D009367:Neoplasm Staging; D009375:Neoplasms, Glandular and Epithelial / Q000473:pathology / Q000628:therapy*; D010051:Ovarian Neoplasms / Q000473:pathology / Q000628:therapy*; D017239:Paclitaxel / Q000008:administration & dosage; D010534:Peritoneal Neoplasms / Q000473:pathology / Q000628:therapy*; D011379:Prognosis; D012189:Retrospective Studies; D015996:Survival Rate
chemical_list: D017239:Paclitaxel; D002945:Cisplatin
keywords: Cisplatin; Disease free survival; HIPEC; Ovarian cancer; Paclitaxel